All relevant data are within the paper and its Supporting Information files. The microarray data is uploaded to the GEO repository per accession number GSE148540.

Introduction {#sec001}
============

Medulloblastoma (MB) is a pediatric brain tumor that can occur in the cerebellum or in the brainstem. Large genomic studies have stratified the tumors into at least four molecular subtypes \[[@pone.0235852.ref001], [@pone.0235852.ref002]\] which has been critical to advance research and clinical understanding of MB. Analyzing the genomic landscape of the tumor cells themselves is important, however it is now well appreciated that the tumor microenvironment has an equally important role in contributing to tumor cell fate. Most importantly, it's been shown that various factors in a tumor microenvironment have significant effects on response to therapy \[[@pone.0235852.ref003], [@pone.0235852.ref004]\]. Therefore, to improve current treatments for MB, understanding how factors and cells within the MB tumor microenvironment may be influencing tumor cells is necessary.

Astrocytes are one of the most abundant cell types in the brain. In healthy conditions, these glial cells via their endfeet extensions maintain homeostasis by regulating neuronal signaling, the blood brain barrier, and neural stem cell populations. In disease states, they become 'activated' through reactive astrogliosis, which shifts their function to become immune modulating, a function shared with microglia in the brain \[[@pone.0235852.ref005]\]. Previously, we have shown that astrocytes influence breast cancer cell invasion and facilitates its metastasis to the brain \[[@pone.0235852.ref006], [@pone.0235852.ref007]\]. In primary brain tumors, such as MB, tumor-associated astrocytes have been found to secrete sonic hedgehog (SHH), which directly increased Nestin expression and proliferation of MB cells derived from a genetic mouse model of SHH MB \[[@pone.0235852.ref008]\]. Metastatic MB tumor-associated astrocytes were also recently identified to secrete chemokine C-C ligand 2 (CCL2), which enriched stem cell properties in MB cells, including expression of CD133 \[[@pone.0235852.ref009]\]. CD133 expression was also found to play a role in glioblastoma stem cells, wherein only CD133 positive cells showed increased invasion and radioresistance upon co-culture with astrocytes \[[@pone.0235852.ref010], [@pone.0235852.ref011]\]. Interestingly, Singh et al. \[[@pone.0235852.ref012]\] first isolated and described MB and glioblastoma stem-like cells using CD133 as the distinguishing marker. Here, CD133 positive cells were tumor initiating and grew as neurospheres *in vitro*, whereas CD133 negative cells lacked those properties \[[@pone.0235852.ref012]\]. Subsequent research on CD133's function in MB has shown that it plays a role in cell survival and therapy resistance through several pathways, including PI3K/AKT \[[@pone.0235852.ref013], [@pone.0235852.ref014]\], Notch \[[@pone.0235852.ref015]\], and STAT3 \[[@pone.0235852.ref009], [@pone.0235852.ref016]\]. Thus, interest in CD133 as both a target and a regulatory molecule in the MB tumor microenvironment is high. In this study, we further investigate astrocytes' influence on CD133 expression in MB cells, and the role of CD133 in contributing to ACM-associated MB phenotypes.

Materials and methods {#sec002}
=====================

Cell culture {#sec003}
------------

Daoy cells were obtained from American Type Culture Collection (ATCC HTB-186). UW228/1 cells \[[@pone.0235852.ref017]\] were generously shared by Dr. John Silber (University of Washington). Daoy and UW228/1 cells were subject to Short Tandem Repeat (STR) analysis to confirm authentication and lack of contamination with other cells types. Both cells types were cultured in Dulbecco's Minimum Essential Medium (DMEM, Thermo Fisher Scientific, Waltham, MA) with the supplementation of 10% fetal bovine serum (FBS, Thermo Fisher Scientific) and 1% antibiotic-antimycotic (Thermo Fisher Scientific) at 37°C in a humidified 5% CO~2~ incubator. For conditioning of MB cells, normal culture media was replaced with the respective conditioned media for the respective lengths of time.

Preparation of conditioned media {#sec004}
--------------------------------

Primary neonatal rat astrocyte conditioned media was prepared as previously described \[[@pone.0235852.ref006], [@pone.0235852.ref007]\]. For microglia conditioned media, primary neonatal rat glial cells were isolated and cultured as previously described \[[@pone.0235852.ref018]\]. Upon culture confluence, cells were dissociated using 0.25% Trypsin EDTA (Thermo Fisher Scientific) and microglia were isolated by fluorescence activated cell sorting (FACS) for CD11b/c positive cells. The sorted cells were cultured on poly-d-lysine coated plates (Sigma-Aldrich, 10 μg/mL) in DMEM with 10% FBS, and purity was confirmed by immunofluorescence and the absence of staining for astrocytes with a GFAP antibody. Conditioned media was collected after 48 h of incubation with microglia cultures of 70% or greater confluence. Mouse embryonic fibroblasts (MEFs) were purchased from ATCC and cultured in DMEM with 10% FBS. Conditioned media was collected after 48 h of incubation with the MEF cultures of 70% or greater confluence. All conditioned media were filtered through 0.4 μM filters prior to use to remove any dead cells or cellular debris.

Reagents and antibodies {#sec005}
-----------------------

Anti CD133 (ab222782; 1:1000) and anti Nestin (ab134017; 1:500) antibodies were purchased from Abcam (Cambridge, MA). Anti Sox2 clone D6D9 (3579; 1:1000) and anti Oct-4A clone C30A3 (2840; 1:500) antibodies were purchased from Cell Signaling (Danvers, MA). Anti L1CAM (AF277; 1:1000) and anti-NFASC (AF2325; 1:500) were purchased from R&D Systems (Minneapolis, MN). Anti NCAM2 (sc-136328; 1:500) was purchased from Santa Cruz Biotechnology (Dallas, TX). Anti β-actin clone AC-40 (GTX11003; 1:10000) was purchased from Genetex (Irvine, CA). Anti CD11b/c clone OX-42 (201807; 1:100) was purchased from BioLegend (San Diego, CA). Anti CD133 clone TMP4 (46-1338-42: 1:200) antibody, Live/Dead fixable red stain (1:200; L34972) and Live/Dead fixable yellow stain (1:200; L34968) were purchased from Thermo Fisher Scientific. Secondary anti-rabbit IgG HRP-linked (7074; 1:10000) and anti-mouse IgG HRP-linked (7076; 1:10000) antibodies were purchased from Cell Signaling. Recombinant bFGF (233-FB) and EGF (236-EG) were purchased from R&D Systems (Minneapolis, MN).

Microarray analysis {#sec006}
-------------------

Cell pellets from Daoy cells cultured in their respective conditions were collected, frozen, and sent to Arraystar, Inc. (Rockville, MD) for RNA isolation and analysis via a Whole Human Genome Oligo Microarray (4 x 44K, Agilent Technologies, Santa Clara, CA). Genes with \> 2 fold change and a *p*-value ≤ 0.05 were considered differentially expressed. Arraystar assisted in the generation of heat map and volcano plots. Microarray data has been deposited to Gene Expression Omnibus (GEO) under accession number GSE148540.

Real time qPCR {#sec007}
--------------

Total RNA was isolated using TRIzol reagent (Thermo Fisher Scientific) following the manufacturer's protocol. Total cDNA was made from 3μg RNA using SuperScriptIII reverse transcriptase (Thermo Fisher Scientific). qPCR was ran using TaqMan pre-designed probes and reagents (Thermo Fisher Scientific). The comparative Ct method was used to analyze mRNA levels using 18S as the normalization control. The following TaqMan probes were used: *L1CAM* (Hs01109748_m1); *NCAM2* (Hs00189850_m1); *NFASC* (Hs00391791_m1); *18S* (Hs99999901_s1).

Adhesion assay {#sec008}
--------------

This assay was performed similar to previously described \[[@pone.0235852.ref019]\]. Briefly, 96-well culture plates were coated with 10 μg/mL fibronectin (Sigma-Aldrich) for 1 h at 37°C followed by blocking with 10 mg/mL heat denatured bovine serum albumin (BSA; Rockland Immunochemicals, Inc., Limerick, PA) in PBS for 45 mins at room temperature. Plates were washed prior to use. MB cells were cultured in the respective conditions for 48 h prior to being harvested and re-seeded at 10,000 cells per well in the same media they were cultured in. Cells were seeded in quadruplicate wells and allowed to adhere for 1 h at 37°C in a humidified 5% CO~2~ incubator. Cells were washed thoroughly with light uniform tapping on the plates with each wash, fixed using 4% PFA, and stained with crystal violet. Brightfield images were captured using a Keyence BZ-X microscope (Osaka, Japan) at 10X magnification. Stained cells were dissolved in 30 μL 2% sodium dodecyl sulfate and optical density was assessed at 595 nm. The adherent cells were quantified either by calculating the average number of cells per image, three images per well, or by the OD 595 values.

Boyden chamber invasion assay {#sec009}
-----------------------------

Serum starved MB cells were seeded in the upper wells of 24-well Boyden chamber Matrigel coated invasion inserts (BD Biosciences). The inserts were placed in wells with normal or conditioned media and incubated at 37°C in a humidified 5% CO~2~ incubator for the indicated time points. The inserts were then fixed in 4% PFA for 15 mins at room temperature, and then stained with crystal violet (Sigma). The cells remaining in the upper well were removed with a cotton swab. The invasive cells were imaged using both a Zeiss Axio Observer Z1 (Oberkocken, Germany) at 10X magnification and the Keyence BZ-X microscope (Osaka, Japan), also at 10X magnification. The invasive cells were quantified by calculating the average number of cells per image, five images per insert.

Zebrafish xenotransplant MB cell injections {#sec010}
-------------------------------------------

Zebrafish work was performed under approved AUA320 protocol by the MCW IACUC committee. We utilized 48 hours post fertilization (hpf) embryos of the *Tg(flk*:*mCherry)* reporter line which has red fluorescent vasculature crossed on an *Absolut*^*+/+*^ background (*ednrbl*^*-/-*^*mitfa*^*-/-*^) to enable complete transparency through adulthood. Prior to injection, embryos were manually dechorionated, screened for vascular mCherry expression, and anesthetized with tricaine. Daoy cells stably expressing m-Emerald were cultured for 48 h in control media or ACM. Cells were collected and brought to a single cell suspension in PBS + 5% FBS at a concentration of 50--100 cells in 1--4 nL (optimized previously by dispensing the injected volume into oil on a microscope slide and manually counting). Cells were then loaded into a pulled glass microneedle broken to approximately 15 μm internal and 18 μm external diameters. The microneedle was driven by a WPI pv820 Pneumatic Picopump. Cells were microinjected into the visible hindbrain ventricle of the embryos, positioned using a soft agarose mold in alignment with the injection apparatus. Two hours after injection, embryos to be imaged were anesthetized and laterally mounted in 1% agarose on glass bottom dishes, with E2 buffer covering the top.

Zebrafish xenotransplant confocal imaging and quantification {#sec011}
------------------------------------------------------------

A LSM510 Meta confocal microscope (Carl Zeiss, Jena, Germany) was used for the time-lapse imaging of the xenotransplanted cells. The microscope was programmed to take images every three mins for 24 h, spanning the entire depth of cells injected. The imaging chamber was kept humidified and at 32°C (temperature pre-determined to keep both embryos and cells alive) with 5% CO~2~ \[[@pone.0235852.ref020]\]. To analyze cell movement and morphology of the time lapse images, Volocity software (PerkinElmer, Waltham, MA) was used. Individual cells were tracked manually, and the positions were then connected to determine the movement and path of each visible cell. Additionally, a reference point on the vasculature of the fish was manually tracked to account for any movement of the embryo during the time lapse, which was then subtracted from the calculation movement of the MB cells. For every image, the relative location/center of each cell was recorded for X, Y, and Z planes. To calculate total distance moved of each cell, the absolute change in location was calculated from each previous position and the sums from the entire time-lapse calculated (with any change in distance/location of the reference point subtracted at every position, prior to taking the sum). Total displacement was calculated by taking the square root of the sums of movement in X, Y, and Z planes. Not all cells remained within the visible field for the entirety of the 24 h time-lapse, therefore total distance and displacement were calculated for the first 250 frames, or about 12.5 h. To analyze cell morphology, cellular protrusions were measured. At every 20 frames, the diameter of each visible cell and the length of any protrusions were measured using Volocity software.

Flow cytometry analysis {#sec012}
-----------------------

Cells were trypsinized, collected, and stained with anti-CD133 antibody as per manufacturer's recommendation, for 30 mins at 4°C. Dead cell exclusion stain was also included and thus CD133 expression was analyzed only on viable cells. Samples were acquired on LSR Fortessa X20 (BD) and data was analyzed using FlowJo software (Treestar, Ashland, OR).

Neurosphere formation assay {#sec013}
---------------------------

MB cells were brought to a single cell suspension in serum free media. For neurosphere formation cultures, cells were seeded at 0.5 x 10^6^ cells/mL on low-attachment plates in their control or experimental media, in the presence of 20 ng/mL bFGF and 20 ng/mL EGF. Serum free ACM was collected by culturing astrocytes in DMEM (high glucose, no glutamine, no phenol red, Thermo Fisher Scientific) and collecting the supernatant after 48 h. Control media is DMEM alone, and as a positive control condition for sphere formation, DMEM was mixed 1:1 with Ham's F12 nutrient mix (Thermo Fisher Scientific). At 48 h, cells were imaged using a Keyence BZ-X microscope. In a six-well plate, 20 pre-programmed brightfield images per well were taken at 4X magnification with 1.7X digital zoom applied. The images were analyzed using Keyence analysis software, where sphere diameter was measured. To quantify, all spheres greater than 75 μm in diameter were measured and counted. Representative images used for visualization of the neurospheres were taken at 10X magnification and 1.8X digital zoom was applied. Measurement of neurosphere size was also done previously using a rough calibration of pixels to micrometer (μm), and then used ImageJ for further data processing. Both methods (Keyence software analysis and ImageJ analysis) yielded similar data.

siRNA knockdowns {#sec014}
----------------

Trilencer-27 short-interfering RNAs (siRNAs) targeting human *CD133* were pre-designed by and purchased from Origene (SR305838; Rockville, MD). The sequence of *siCD133-1* is `5’-GGCAGAUAGCAAUUUCAAGGACUTG-3’`; and the sequence of *siCD133-2* is `5’-GGCUUGGAAUUAUGAAUUGCCUGCA-3’`. Gene knockdown was validated by qRT-PCR and western blotting. siRNAs were transfected into Daoy cells according to the manufacturer's protocol. Briefly, Daoy cells were seeded to be 50--70% confluent that the time of transfection. Per well of a 6-well plate, a complex of 400 μL Opti-MEM (Thermo Fisher Scientific), 1 μL Lipofectamine RNAiMax (Thermo Fisher Scientific), and *CD133* siRNA (10 nM) or Scramble siRNA (10 nM) were added to the cells for 24--48 h.

Protein isolation and immunoblotting {#sec015}
------------------------------------

Cells cultured for protein isolation were washed with PBS prior to adding cold RIPA buffer (Thermo Fischer Scientific) supplemented with protease (cOmplete EDTA-free Protease Inhibitor cocktail, Roche, Basal, Switzerland) and phosphatase (PhoseSTOP, Roche) inhibitors. Lysates were centrifuged at 16000xg for 20 mins at 4°C followed by the collection of supernatant. Protein quantification was determined by DC Protein Assay (Bio-Rad Laboratories, Hercules, CA). Total protein lysates were loaded onto 4--20% SDS-PAGE gels (Mini-PROTEAN TGX Precast Protein Gels, Bio-Rad Laboratories) and transferred to nitrocellulose membrane. Blots were blocked at room temperature for 1 h in 5% BSA in TBST prior to incubation with primary antibody at 4°C overnight. After washing, blots were incubated with HRP-linked secondary antibodies for 1 h at room temp. Chemiluminescent signal was detected using enhanced chemiluminescent (ECL) HRP substrate (SuperSignal West Pico and Fempto solutions, Thermo Fisher Scientific) and imaged using a ChemiDoc Imaging System (Bio-Rad Laboratories). Quantification of optical densitometry was performed using ImageJ software.

Statistical analysis {#sec016}
--------------------

All experiments performed had a minimum of three biological replicates. Statistical analysis was done using GraphPad Prism software (GraphPad Software, Inc., San Diego, CA). Data were presented as the mean ± standard deviation (SD) calculated by two-tailed Student's *t*-test, one-way analysis of variance (ANOVA), or two-way ANOVA, as appropriate. For all analyses, a p-value ≤ 0.05 was considered statistically significant.

Results {#sec017}
=======

Astrocyte secreted factors alter MB cell gene expression {#sec018}
--------------------------------------------------------

To investigate astrocytes effect on MB tumor cells, we performed a hypothesis-generating microarray-based gene expression analysis on MB cells post culturing in ACM. In the past, culturing breast cancer cells in ACM has shown profound gene expression changes \[[@pone.0235852.ref006], [@pone.0235852.ref007]\]. ACM was used in place of culture media for Daoy cells for 48 hours (h) ("ACM conditioned", [S1A Fig](#pone.0235852.s001){ref-type="supplementary-material"}). Gene expression was quantified by microarray, and the results are shown through a hierarchical clustering heat map ([Fig 1A](#pone.0235852.g001){ref-type="fig"}) and volcano plot ([Fig 1B](#pone.0235852.g001){ref-type="fig"}). When comparing ACM-conditioned MB cells to control cultured MB cells, there were a total of 973 differentially expressed genes, 756 of which were greater than two-fold differentially expressed (*p*≤0.05) ([Fig 1B](#pone.0235852.g001){ref-type="fig"}, red squares). Gene expression pathway analysis was performed on all genes greater than two-fold differentially expressed (*p*≤0.05) in ACM-cultured cells in comparison to control. Of note, functional mapping of genes to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways found an enrichment in genes related to cell adhesion upregulated in ACM-treated MB cells. Adhesion-related networks were also identified using Ingenuity Pathway Analysis software (Qiagen) ([S1B Fig](#pone.0235852.s001){ref-type="supplementary-material"}). We also validated three microarray targets (*NFASC*, *L1CAM*, *NCAM2*) related to adhesion network, which were up in ACM-treated MB cells at both mRNA ([S1C Fig](#pone.0235852.s001){ref-type="supplementary-material"}) and proteins levels ([S1D Fig](#pone.0235852.s001){ref-type="supplementary-material"}). These results demonstrated the breadth of effects of astrocyte-secreted factors on MB cells, and pointed to adhesion-related phenotypes.

![Astrocyte secreted factors alter Daoy MB cell gene expression, adhesion and invasion.\
(A) Hierarchical clustering heat map of differentially expressed genes in Astrocyte Conditioned Media (ACM) cultured cells compared to DMEM cultured (control) cells. Image modified from Arraystar (Rockville, MD) (B) Volcano plot of differentially expressed genes between ACM cultured and control cells. The *y*-axis represents the--log10 of the p-value while the *x*-axis represents the log2 of gene expression fold change. All differentially expressed genes are shown as squares, with the red squares representing the differentially expressed genes (≥2 fold up or down) with statistical significance (p≤0.05) in ACM cultured cells. Image modified from Arraystar (Rockville, MD) (C) Fold change of the number of adhered cells per image in ACM conditioned cells compared to control (DMEM cultured, set to 1). (D-E) Average number of invaded Daoy cells per image, counted on the lower surface of Boyden chambers, with the respective media in the lower well during incubation. (F) Representative images of invaded cells on the lower surface of the Boyden chambers. Quantified values expressed as mean +/- SD. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001.](pone.0235852.g001){#pone.0235852.g001}

Astrocyte-secreted factors increase invasion and adhesion of MB cells {#sec019}
---------------------------------------------------------------------

To confirm the up regulated cell adhesion gene expression results, we functionally tested ACM-treated MB cells on a two-dimensional adhesion plate assay coated with fibronectin. Here, Daoy and UW228/1 cells were cultured in ACM or control DMEM for 48 h prior to reseeding for 1 h in fresh culture media. Daoy cells cultured in ACM adhered more strongly to the fibronectin-coated plates compared to control cultured Daoy cells ([Fig 1C](#pone.0235852.g001){ref-type="fig"}). UW228/1 cells showed no difference in adhesion between ACM-cultured and control cultured cells ([S2A Fig](#pone.0235852.s002){ref-type="supplementary-material"}). We next assessed cell invasion based on our past data where ACM culturing increased invasion of breast cancer cells (MDA-MB-231), lung cancer adenocarcinoma cells (H2030) and sarcoma cells (S180) \[[@pone.0235852.ref006]\]. Using an *in vitro* Boyden chamber invasion assay, we assessed whether ACM has an effect on the invasion of MB cells. Daoy and UW228/1 cells demonstrated increased invasion with ACM in the lower chamber compared to all control conditions: DMEM, DMEM + 10% FBS, DMEM + 5% FBS, and DMEM SF (Serum Free) ([Fig 1D and 1G](#pone.0235852.g001){ref-type="fig"}, [S2B Fig](#pone.0235852.s002){ref-type="supplementary-material"}). Additionally, ACM SF in the lower chamber induced invasion of Daoy cells similar to that of ACM with serum, demonstrating Daoy cell invasion in ACM conditions was serum-independent ([Fig 1D and 1G](#pone.0235852.g001){ref-type="fig"}). UW228/1 cell showed less invasion in response to ACM SF compared to normal ACM, however ACM still induced significantly greater invasion compared to all DMEM controls ([S2B Fig](#pone.0235852.s002){ref-type="supplementary-material"}).

To determine if this effect on invasion was astrocyte specific or a common response to conditioned culture media from other cells, we also assayed Daoy and UW228/1 cell invasion using conditioned media (normal and SF) from other cell types. We isolated, cultured, and collected conditioned media from neonatal rat microglia. Daoy and UW228/1 cells showed invasion with microglia conditioned media in the lower chamber, however invasion significantly decreased with microglia SF conditioned media ([Fig 1E and 1G](#pone.0235852.g001){ref-type="fig"}, [S2C--S2E Fig](#pone.0235852.s002){ref-type="supplementary-material"}). To test conditioned media from another highly proliferative cell type, mouse embryonic fibroblasts (MEF) cells were cultured and conditioned media was collected. Similarly, Daoy and UW228/1 cell showed substantial invasion in response to MEF conditioned media, however this invasion was largely ablated when serum was not present ([Fig 1F and 1G](#pone.0235852.g001){ref-type="fig"}, [S2D--S2E Fig](#pone.0235852.s002){ref-type="supplementary-material"}).

Taken together, these data demonstrate that, in addition to the MB cell adhesion gene signature, astrocyte-secreted factors present in ACM, induce phenotypic changes that increase adhesion to fibronectin and increase chemotactic invasion through matrigel. Further, the invasion response is specific to conditioned media from astrocytes, and the invasion is for the most part, serum-independent.

MB cells conditioned in ACM prior to xenograft show increased cellular protrusion formation {#sec020}
-------------------------------------------------------------------------------------------

Next, we wanted to investigate whether these phenotypic changes seen *in vitro* also translated to changes in cell behavior *in vivo*. Recent methodologies have established zebrafish as an effective vertebrate system to visualize xenografted tumor cell behavior and movement \[[@pone.0235852.ref021]\]. Specifically, pediatric brain tumors have been successfully xenografted in zebrafish for drug screening purposes \[[@pone.0235852.ref022], [@pone.0235852.ref023]\]. A zebrafish xenotransplant model combined with confocal time-lapse imaging were used to determine the behavior of astrocyte conditioned MB cells *in vivo*. Because of the transparency of the embryonic zebrafish model, it provides the ability to not only visualize cell migration, but also cell morphology changes as related to the changes in adhesion and invasion seen *in vitro*. In addition, the zebrafish adaptive immune system is not developed until 3--4 weeks post fertilization (wpf) \[[@pone.0235852.ref016], [@pone.0235852.ref024], [@pone.0235852.ref025]\], therefore the short-term imaging within 24 h of injection bypassed the need to immunocompromise the animals chemically, genetically or by γ-irradiation. Daoy cells stably expressing mEmerald (variant of GFP) protein were generated and subsequently cultured in either ACM or control media for 48 h and microinjected into the hindbrains of 48 hours post fertilization (hpf) embryos. The approximate MB cell location and appearance post microinjection is marked ([Fig 2A](#pone.0235852.g002){ref-type="fig"}). Injected zebrafish embryos were then laterally mounted in agarose and imaged via time-lapse confocal microscopy for 24 h ([S1 Video](#pone.0235852.s003){ref-type="supplementary-material"}). Cells were analyzed by tracking their movement ([Fig 2B](#pone.0235852.g002){ref-type="fig"}) and measuring protrusions ([Fig 2C](#pone.0235852.g002){ref-type="fig"}) using Volocity software (PerkinElmer). Overall, total distance, displacement, and average displacement per frame were unchanged by culturing Daoy cells in ACM prior to injection ([Fig 2D--2F](#pone.0235852.g002){ref-type="fig"}). Interestingly, ACM conditioning distinctly changed MB cell morphology by increasing the overall occurrence ([Fig 2G](#pone.0235852.g002){ref-type="fig"}) and size of cellular protrusions ([Fig 2H](#pone.0235852.g002){ref-type="fig"}) of MB cells in the zebrafish brain. Thus, ACM-conditioned MB tumor cells do possess phenotypic activity *in vivo* that resembles the observed *in vitro* adhesive phenotype.

![ACM conditioning changes Daoy MB cell morphology *in vivo*.\
(A) Representative images of cells (yellow arrow) after injection into the hindbrains of 48 hpf *Absolut*^*+/+*^ *Tg(flk*:*mCherry)* zebrafish embryos. Right panel is higher magnification. Scale bar is 250 μm. (B) Representative image of injected cells at the beginning of the time-lapse imaging. Colored lines show the tracked movement of individual cells during the time-lapse imaging, and the white line shows the tracked reference point movement. Scale bar is 50 μm. (C) Representative image of injected cell protrusion (yellow arrow). Scale bar is 50 μm. (D-F) Quantification of injected cell migration, represented by total cell displacement (D) and total distance (E) moved by all cells in first 12.5 hours (h) of imaging, and average displacement/frame (F) of cells through entire 24 h time lapse. (G-H) Quantification of injected Daoy cell protrusion formation, measured by average percent of visible cells with protrusions (G) and protrusion length to cell body size ratio (H). Quantified values expressed as mean +/- SD. \*\*p\<0.01, \*\*\*p\<0.001.](pone.0235852.g002){#pone.0235852.g002}

Astrocyte-secreted factors increase CD133 surface expression and neurosphere characteristics in MB cells {#sec021}
--------------------------------------------------------------------------------------------------------

The hypothesis from the microarray array and subsequent confirmation by adhesion assay *in vitro* that ACM-conditioned MB cells showed more adhesion suggested that molecules involved in adhesion and MB cell invasion will be functionally relevant on ACM-conditioned MB cells. It is known that Daoy MB cells cultured as neurospheres express higher CD133 (a pentaspanin transmembrane glycoprotein that has been associated with protrusion formation and localization \[[@pone.0235852.ref026]\]) when compared to Daoy cells cultured in an adherent monolayer \[[@pone.0235852.ref027], [@pone.0235852.ref028]\]. Further, these neurosphere-forming MB cells were more invasive *in vitro* \[[@pone.0235852.ref027]\], and CD133 expression is high in disseminated human MB tumors \[[@pone.0235852.ref009]\]. Thus, we investigated CD133 surface expression in ACM-conditioned MB cells compared to control-media conditioned MB cells using flow cytometry. We also analyzed CD15 expression, another protein which has been shown to be expressed on MB stem-like cells \[[@pone.0235852.ref029]\], specifically in the SHH subtype. Daoy cells were cultured for 24, 48, and 72 h in either ACM or control media prior to analysis. ACM culturing increased CD133 surface expression 2-fold at 24 and 48 h, and close to 3-fold at 72 h in comparison to control cultured Daoy cells ([Fig 3A](#pone.0235852.g003){ref-type="fig"}). We did not observe an effect of ACM culturing on CD15 expression at any time point ([Fig 3B](#pone.0235852.g003){ref-type="fig"}). We next assessed whether ACM culturing enhances neurosphere formation of Daoy cells. Daoy cells were dissociated into a single cell suspension and seeded in ACM, DMEM, or positive control DMEM:F12 media in neurosphere culturing conditions (all SF, low attachment culture dishes supplemented with bFGF and EGF). At 48 h, brightfield images were taken and quantified by the number of neurospheres imaged as well as the diameter of the neurospheres. Culturing in DMEM alone produced almost no neurosphere formation ([Fig 3C and 3D](#pone.0235852.g003){ref-type="fig"}). However, ACM and DMEM:F12 conditions induced robust neurosphere formation at 48 h, where the size and number of neurospheres in ACM conditions were similar to that of the positive control ([Fig 3B and 3C](#pone.0235852.g003){ref-type="fig"}). Two different methods of neurosphere quantification were performed as explained in the materials and methods section. Next, we probed Daoy neurosphere lysates for neural stem cell markers Nestin, Oct-4A and Sox2 \[[@pone.0235852.ref030]--[@pone.0235852.ref032]\]. Nestin, an intermediate filament protein, was increased in ACM and DMEM:F12 cultured neurospheres, compared to DMEM alone ([Fig 3E](#pone.0235852.g003){ref-type="fig"}). These results are consistent with previous reports that show high Nestin expression in CD133 positive MB stem-like cells \[[@pone.0235852.ref012], [@pone.0235852.ref015], [@pone.0235852.ref028]\]. Oct-4A is a transcription factor which has been associated with poor outcomes in MB patients, in addition to increasing neurosphere formation and invasion upon overexpression in Daoy cells \[[@pone.0235852.ref033], [@pone.0235852.ref034]\]. Here, Daoy neurospheres cultured in DMEM:F12 and ACM conditions expressed higher Oct-4A compared to control cultured neurospheres ([Fig 3F](#pone.0235852.g003){ref-type="fig"}). A third neural stem cell transcription factor, Sox2 \[[@pone.0235852.ref032]\], showed no difference in expression between DMEM and ACM-cultured neurospheres, and extreme variability in DMEM:F12 neurospheres ([Fig 3G](#pone.0235852.g003){ref-type="fig"}) Together, these data demonstrate that ACM conditioning of MB cells increases CD133 surface expression, Nestin expression, Oct-4A expression and neurosphere formation in Daoy cells.

![ACM effects on CD133 surface expression and neurosphere formation.\
(A) Percentage of CD133 positive cells cultured in ACM or DMEM (control), measured by flow cytometry at 24, 48, and 72 h. (B) Percentage of CD15 positive cells cultured in ACM or DMEM (control), measured by flow cytometry at 24, 48, and 72 h. (C) Representative images of Daoy cells cultured in neurosphere conditions using the respective media for 48 h. Scale bar is 100 μm. (D) Total number of neurospheres counted in all images between 75--100 μm or \>100 μm at 48 h, cultured in the respective media. (E) Western blot analysis of Nestin, (F) Oct-4A and (G) Sox2 expression in respective neurosphere culturing conditions at 48 h. β-actin served as a loading control (left). Quantification of relative fold change of Nestin, Oct-4A and Sox2 expression, measured by the densitometry of western blot bands and normalized to β-actin (DMEM condition set to 1) (right). Quantified values expressed as mean +/- SD. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001.](pone.0235852.g003){#pone.0235852.g003}

Knockdown of CD133 in MB cells reduces adhesion, invasion, and neurosphere formation {#sec022}
------------------------------------------------------------------------------------

To determine the relevance of increased CD133 surface expression on ACM-MB cells, we utilized short interfering RNA (siRNA) to knockdown *CD133* expression, followed by functional assessment of *CD133*'s role in adhesion, invasion, and neurosphere formation. Two separate 27-mer siRNAs (*siCD133-1* and *siCD133-2*) targeting different regions of *CD133* mRNA were utilized, and knockdown efficiency was assessed by quantifying gene and protein expression after transfection with *siCD133-1*, *siCD133-2*, *scramble* siRNA, as well as non-transfected cells. CD133 protein was effectively knocked down by *siCD133-1* and *siCD133-2* by 66% and 80%, respectively ([Fig 4A](#pone.0235852.g004){ref-type="fig"}).

![Short interfering RNA (siRNA) knockdown of *CD133* alters Daoy MB cell function.\
(A) Western blot analysis of CD133 expression 48 h after transfection with *siCD133-1*, *siCD133-2*, scramble siRNA, or no transfection. β-actin served as a loading control (left). Quantification of relative percent CD133 expression, measured by the densitometry of western blot bands and normalized to β-actin (Scramble set to 100%) (right). (B) Fold change of the number of adhered cells per image after transfecting with *siCD133-1*, *siCD133-2* or scramble siRNA, then culturing in ACM or DMEM (control) (DMEM scramble set to 1). (C) Average number of invading cells per image, counted on the lower surface of Boyden chambers with ACM or DMEM in the lower well, after transfecting with *siCD133-1*, *siCD133-2* or scramble siRNA. (D) Total number of neurospheres counted with diameter length between 75--100 μm or \>100 μm. Cells were transfected with *siCD133-1*, *siCD133-2* or scramble siRNA and then cultured in the respective media for 48 h. Quantified values expressed as mean +/- SD. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001.](pone.0235852.g004){#pone.0235852.g004}

Daoy cells were transfected prior to being cultured in either ACM or control media for 48 h before being reseeded in the adhesion assay described in the methods. When cultured in ACM, *siCD133-1* and *siCD133-2* transfected cells were significantly less adhesive than *scramble* siRNA transfected cells ([Fig 4B](#pone.0235852.g004){ref-type="fig"}). Interestingly, in control cultured cells, *CD133* knockdown had no effect on adhesion ([Fig 4B](#pone.0235852.g004){ref-type="fig"}), suggesting that CD133 may work together with another factor in ACM to increase *in vitro* adhesion.

Similarly, *CD133* was knocked down in Daoy cells prior to seeding the cells in the upper well of the Boyden invasion chamber, with either ACM or DMEM +10% FBS in the lower well. Overall, *CD133* knockdown cells showed significantly less invasion with both ACM and DMEM in the lower well in comparison to scramble transfected cells ([Fig 4C](#pone.0235852.g004){ref-type="fig"}). With ACM in the lower well, invasion decreased in *siCD133-1* and *siCD133-2* transfected MB cells by a combined average of 46% compared to *scramble* siRNA transfected cells. With DMEM in the lower well, *siCD133-1* and *siCD133-2* transfected cells showed about 61% less invasion compared to *scramble* siRNA transfected cells ([Fig 4C](#pone.0235852.g004){ref-type="fig"}). We also assessed neurosphere formation (DMEM, ACM and DMEM:F12 neurosphere conditions) with the *CD133* knockdown MB cells. As observed before, non-transfected cells cultured in DMEM alone showed very little neurosphere formation, which remained unchanged in *CD133* knockdown and *scramble* siRNA conditions ([Fig 4D](#pone.0235852.g004){ref-type="fig"}). In both ACM and DMEM:F12 culture conditions, neurosphere formation was significantly reduced in both size and number in *CD133* knockdown cells compared to *scramble* siRNA transfected cells ([Fig 4D](#pone.0235852.g004){ref-type="fig"}).

The above results suggest that upon ACM conditioning, the observed increase in CD133 surface expression is associated with the displayed MB phenotypes of increased adhesion, invasion, and neurosphere formation.

Discussion {#sec023}
==========

The MB microenvironment is comprised of various cell types, and depending on where the tumor is located, cells such as astrocytes, microglia, and others (neuronal cells, endothelial cells, pericytes, neural stem cells, ependymal cells and connective tissue that make up the meningeal layers) \[[@pone.0235852.ref035]\] can interact with MB cells. Our study focuses on astrocytes and their role in the MB microenvironment. Salient features of this study include: (a) Astrocytes' influence MB cells through up regulation of CD133 expression, a protein known to be important for MB tumorigenicity and survival. (b) The ACM-mediated increase in MB CD133 expression plays a role in MB cell invasion, adhesion, and neurosphere formation.

To investigate astrocytes' role in the MB microenvironment, we used ACM collected from primary astrocyte cultures to assess its effect on MB cell function. With this model, we can observe paracrine signaling from factors secreted by astrocytes and downstream effects, versus the effects of physical interactions. We found that culturing human MB cells in ACM increased adhesion to fibronectin in Daoy cells, as well as invasion in both Daoy and UW228/1 cells. Previous research from our group found ACM to have a similar effect on invasion of other tumor cell types, including breast cancer cells \[[@pone.0235852.ref006], [@pone.0235852.ref007]\]. Moreover, those studies showed that culturing MDA-MB-231 breast cancer cells in ACM led to an increase in brain metastases in a mouse xenograft model. Interestingly, when we cultured MB cells in ACM prior to a zebrafish xenotransplant, we did not see a difference in cell migration during the 24 h imaging time frame; however, long-term metastasis could not be assessed in this model. We did observe increased MB cell protrusion formation in the zebrafish brain, which may be related to the increased adhesion or CD133 expression seen *in vitro*, as there is evidence in the literature for both \[[@pone.0235852.ref026], [@pone.0235852.ref036]\], however this was not investigated here.

The ACM-induced CD133 expression was indeed proven to be functionally significant. Knockdown of *CD133* reduced neurosphere formation in the positive control neurosphere condition (DMEM:F12), which is consistent with previous studies that have demonstrated enhanced neurosphere formation in FACS-isolated CD133 positive Daoy cells \[[@pone.0235852.ref028], [@pone.0235852.ref037]\]. CD133 also plays a role in ACM-induced neurosphere formation. Knockdown of *CD133* reduced invasion of Daoy MB cells altogether, with both ACM and DMEM in the lower well. CD133's role in MB invasion has not been well defined to this point, limited to correlations with increased expression and invasion or metastasis of MB cells \[[@pone.0235852.ref038]--[@pone.0235852.ref040]\]. One such correlative study compared Daoy adherent and neurosphere cultures and found higher *CD133* expression and migration in neurosphere cells \[[@pone.0235852.ref027]\]. Our research corroborates this correlation by providing direct evidence that CD133 influences Daoy invasion. To date, there has been little work investigating the role of CD133 in cell adhesion. Notably, in ovarian cancer cells, overexpression of *CD133* increased adhesion to mesothelial layers and collagen \[[@pone.0235852.ref041]\]. We investigated CD133's role in adhesion of MB cells. Interestingly, knockdown of *CD133* only reduced adhesion in ACM culturing conditions, however control conditions remained unaffected. This suggests CD133's role in adhesion is dependent on paracrine signaling from astrocytes and may require a yet unknown factor in ACM or downstream signaling event caused by ACM culturing to exert its functional effect on adhesion.

Understanding which factors in ACM that contribute to increasing CD133 expression will increase our mechanistic understanding of how ACM-induced effects may translate into MB outcomes and suggest avenues for intervention. The astrocyte secretome is diverse and thus, there are likely a combination of factors in the ACM influencing the MB phenotypes. CCL2, SHH, and IL-4 are astrocyte-secreted factors which have been shown to promote MB phenotypes \[[@pone.0235852.ref008], [@pone.0235852.ref009], [@pone.0235852.ref042]\]. Interestingly, CCL2 secretion from astrocytes \[[@pone.0235852.ref009]\] was induced by chemotherapy and radiation-induced inflammation and necroptosis in astrocytes. Moreover, the IL-4 secretion was found to come from astrocytes which trans-differentiated from the MB precursor cells in a SHH MB mouse model \[[@pone.0235852.ref042]\]. These reports combined with our findings provide supporting evidence that astrocytes influence the MB microenvironment in distinct ways, which must be considered during the development of anti-MB treatment strategies. As of now, it is not clear what astrocyte factor(s) is responsible for inducing CD133 expression in MB cells in our model. This is a topic of future investigation.

To summarize, this study provides a direct link between an important survival and stem cell protein, CD133, and *in vitro* phenotypes that correlate to poor outcomes in MB malignancy. We also demonstrate that CD133 surface expression is directly affected by paracrine signaling from astrocytes, neighboring cells in the MB microenvironment. Our work and the work of others are increasingly suggestive that CD133 is an important cell surface target in MB, given that CD133 is known for its role in survival and resistance of MB cancer stem cell populations \[[@pone.0235852.ref043]\]. Thus, these questions form the basis of future investigations. Lastly, our studies demonstrate the importance of studying astrocytes and their role in the MB microenvironment to influence MB malignancy.

Supporting information {#sec024}
======================

###### Schematic of ACM collection and use in culturing of MB cells, and microarray validation of select adhesion targets.

\(A\) depicts the ACM collection and treatment of MB cells in a pictorial format. (B) Graphic depiction of adhesion pathways predicted to be altered in ACM cultured Daoy cells based on the microarray data. Image generated using Ingenuity Pathway Analysis (Qiagen) software. (C) qRT-PCR normalized fold change compared to control (DMEM, set to 1) for three adhesion target genes (*NFASC*, *L1CAM* and *NCAM2*) identified as significantly changed in the microarray analysis. (D) Western blot analysis of NFASC, L1CAM, and NCAM2 in the ACM-conditioned and DMEM-conditioned MB cell lysates. β-actin served as a loading control (left). Quantification of relative fold change measured by the densitometry of western blot bands and normalized to β-actin (DMEM condition set to 1) (right). Quantified values expressed as mean +/- SD. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001.

(PDF)

###### 

Click here for additional data file.

###### Conditioned media (CM) effects on adhesion and invasion in UW228/1 cells.

(A-B) Fold change of the number of adhered cells per well, measured by dissolving the stained cells and reading optical density at 595 nm in ACM conditioned cells compared to control (DMEM, set to 1). (B-D) Average number of invaded cells per image, counted on the lower surface of Boyden chambers, with the respective media in the lower well during incubation. Panel C is microglia conditioned media (CM) cells and (D) is mouse embryonic fibroblast (MEF) media conditioning. (E) Representative images of invaded cells on the lower surface of the Boyden chambers in response to various conditioned media are shown. Quantified values expressed as mean +/- SD. \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001.

(TIF)

###### 

Click here for additional data file.

###### Representative zebrafish xenotransplant time-lapse imaging video.

Daoy cells (green) were either cultured in ACM or control (DMEM) media prior to injecting into *Absolut*^*+/+*^ *Tg(flk*:*mCherry)* 48 hpf zebrafish embryos (vasculature is red). Confocal z-stack images were taken every three minutes for 24 h. Images were rendered into a 3-dimensional video using Volocity software.

(AVI)

###### 

Click here for additional data file.

###### 

(PDF)

###### 

Click here for additional data file.
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The image of neurospheres must be changed. The authors must add the pictures with an original magnification grater in order to detect the differences in size following treatments. Moreover, to confirm the stemness of cells treated with ACM, the authors must evaluate stem transcriptional factors such as OCT4, Nanog and Sox2. The authors demonstrate that CD133 is associated with increased adhesion. As the microarray indicates that adhesion genes are increased, the authors should analyze the genes with the highest value for each experimental condition and evaluate how they change. When CD133 is silenced, what do it happens to these genes?

The Discussion section must be revised. It is too speculative. It should be better focused on the importance of results obtained in medulloblastoma treatment.
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It is not clear why the Authors performed a microarray, showing a strong alteration of adhesion gene, but did not investigate the role of any of those genes in MB to establish a mechanist effect.

The Author state that ACM increased the stemness of MB cells, however this was based only on spheroid formation. For instance the spheroid analysis and images are not acceptable, more clear and higher magnification images should be provided and an algorithm to calculate sphere diameter should be used. Then, to show an increase in stemness features only spheres formation it's not enough, the Author should at least show an increase of stem-associated-genes such as Nanog, OCT3/4, and Sox-2 or perform side population assay, or ALDH or any other assay appropriated for MB. This is valid as well for the CD133 knock down.
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Albeit of interest, the paper in its present form requires to be consistently amended in several parts, following all the points highlighted by the two referees. Actually to perform a microarray does not make sense if the altered genes are not investigated and without a confirmation by RT-PCR.

Response: We appreciate the concern here. The microarray was performed as a hypothesis-generating experiment. Based on this experiment, we observed that adhesion pathways (Fig. S1B) were influenced in medulloblastoma tumor cells that were conditioned in astrocyte media. Yes, we did validate the targets. In the revision, we have now included the qPCR (Fig. S1C) and western blot (Fig. S1D) results for select microarray targets related to adhesion (NFASC, L1CAM, NCAM2) that were upregulated in ACM-MB cells.

Moreover, the stemness must be observed by means of the specific genes including at least Nanog and OCT3/4.

Response: We performed Sox2 western blot (Fig. 3F), which is also a stem marker and found no difference between ACM-conditioned and DMEM-conditioned MB cells. Due to current COVID-19 situation, we are unable to perform other stem marker genes as requested. We have therefore made revisions in the text to de-emphasize the stemness point.

Discussion is largely speculative and long. Therefore, the Authors must amend each point raised in the referee\'s comments in their revised paper.

Response: We have made extensive changes to the discussion to make the points that are directly relevant to the data in the manuscript, and those that support or oppose existing literature on this subject. We provide below a point-by-point response to the reviewer queries.

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

Response: We have ensured that the manuscript and its file names meet PLOS ONE style requirements.

3\. Please amend your current ethics statement to include the full name of the ethics committee that approved your specific study.

For additional information about PLOS ONE submissions requirements for ethics oversight of animal work, please refer to <http://journals.plos.org/plosone/s/submission-guidelines#loc-animal-research>. Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the "Ethics Statement" field of the submission form (via "Edit Submission").

Response: The requested changes have been made.

4\. We note that you are reporting an analysis of a microarray, next-generation sequencing, or deep sequencing data set. PLOS requires that authors comply with field-specific standards for preparation, recording, and deposition of data in repositories appropriate to their field. Please upload these data to a stable, public repository (such as ArrayExpress, Gene Expression Omnibus (GEO), DNA Data Bank of Japan (DDBJ), NCBI GenBank, NCBI Sequence Read Archive, or EMBL Nucleotide Sequence Database (ENA)). In your revised cover letter, please provide the relevant accession numbers that may be used to access these data. For a full list of recommended repositories, see <http://journals.plos.org/plosone/s/data-availability#loc-omics> or <http://journals.plos.org/plosone/s/data-availability#loc-sequencing>.

Response: We plan to submit the microarray data to the GEO database and will provide the reference number upon completion.

5\. In your Methods section, please provide additional details regarding the cell lines used in your study. For the UW228/1 cell line, please address whether the cell line was verified, and if so, how it was verified. Please also ensure that you have cited the original paper describing this cell line. For the Daoy cell line, please include the ATCC catalog number. For more information on PLOS ONE\'s guidelines for research using cell lines, see <https://journals.plos.org/plosone/s/submission-guidelines#loc-cell-lines>.

Response: Short Tandem Repeat (STR) genetic profiling for cell authentication was performed on UW228/1 cells. Although these cells do not have a public STR profile for positive comparison, the STR analysis confirmed no match with any other cell lines within the DSMZ database in addition to confirming a single donor source. This is noted in the revised manuscript.

6\. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission's figures or Supporting Information files. This policy and the journal's other requirements for blot/gel reporting and figure preparation are described in detail at <https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements> and <https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files>. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: <https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels>.
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In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at <plosone@plos.org> if you have any questions.

Response: This information has been provided in the supporting information (file "S1_raw_images").

 

Reviewers\' comments:

We thank both reviewers for evaluating our manuscript and providing constructive comments.

Reviewer \#1:

The image of neurospheres must be changed. The authors must add the pictures with an original magnification grater in order to detect the differences in size following treatments.

Response: Yes, we realize this concern but due to COVID-19 related lab closures, hibernations, and other issues, it is unclear when institution will open up. Deliveries are also delayed these days, and thus the May 10 deadline is not feasible. Thus, we are unable to perform additional new experiments to generate spheres for better high power imaging. For better visualization of the spheres, we enlarged the representative images (Fig 3) as much as possible while maintaining good image quality. In terms of size determinations, we have used two independent methods of quantifications for images taken on two different scopes (Zeiss and Keyence), which has been explained in detailed later (rev. 2 query below), and showed the same result. We also excluded spheres less than 75 �m to avoid including aggregates in our quantification. Thus, we are confident with our neurosphere quantification.

Moreover, to confirm the stemness of cells treated with ACM, the authors must evaluate stem transcriptional factors such as OCT4, Nanog and Sox2.

Response: We performed Sox2 western blot (Fig. 3F), which is also a stem marker and found no difference between ACM-conditioned and DMEM-conditioned MB cells. Due to current COVID-19 situation, we are unable to perform other stem marker genes as requested. We have therefore made revisions in the text to de-emphasize the stemness point.

The authors demonstrate that CD133 is associated with increased adhesion. As the microarray indicates that adhesion genes are increased, the authors should analyze the genes with the highest value for each experimental condition and evaluate how they change. When CD133 is silenced, what do it happens to these genes?

Response: The microarray was performed as a hypothesis-generating experiment. Based on this experiment, we observed that adhesion pathways (Fig. S1B) were influenced in medulloblastoma tumor cells (Daoy) that were conditioned in astrocyte media. Yes, we did validate the targets. In the revision, we have now included the qPCR (Fig. S1C) and western blot (Fig. S1D) results for select adhesion gene targets (NFASC, L1CAM, NCAM2) upregulated in ACM-MB cells. We never claimed that the adhesion gene targets NFASC, L1CAM and NCAM2 were downstream of CD133, and thus did not see the rationale for performing this experiment.

The Discussion section must be revised. It is too speculative. It should be better focused on the importance of results obtained in medulloblastoma treatment.

Response: We have made extensive changes to the discussion to make the points that are directly relevant to the data in the manuscript, and those that support or oppose existing literature on this subject. Please see revised manuscript with track changes.

Reviewer \#2:

It is not clear why the Authors performed a microarray, showing a strong alteration of adhesion gene, but did not investigate the role of any of those genes in MB to establish a mechanist effect.

Response: We apologize if the microarray rationale was not clear. The microarray was performed as a hypothesis-generating experiment. Based on this experiment, we observed that adhesion pathways (Fig. S1B) were influenced in medulloblastoma (MB) tumor cells that were conditioned in astrocyte media. Yes, we did validate the adhesion gene targets. In the revision, we have now incuded the qPCR (Fig. S1C) and western blot (Fig. S1D) results for select targets (NFASC, L1CAM, NCAM2) upregulated in ACM-MB cells. We also performed knockdown of L1CAM target but did not observe changes in adhesion (data not shown). Thus, we rationalized redundancy in the up regulated adhesion molecules, and focused on a known CD133 adhesion molecule that is associated with MB progression \[1\]. Without the microarray data, we would not have hypothesized that the adhesion pathway was involved in astrocyte conditioned MB cell phenotype. Some of these explanations have been included in the revised MS.

The Author state that ACM increased the stemness of MB cells, however this was based only on spheroid formation. For instance the spheroid analysis and images are not acceptable, more clear and higher magnification images should be provided and an algorithm to calculate sphere diameter should be used.

Response: We have now de-emphasized the stemness point, because our Sox2 western blot data showed great variability between DMEM-conditioned MB cells and ACM-conditioned MB cells (Fig. 3F), which precludes any conclusion. We actually performed two independent methods of quantification for images taken under two different scopes. We initially took pictures on Zeiss scope. To measure diameter, we performed a rough calibration of pixels to micrometer (�m), and then used ImageJ for further data processing. In the second Keyence scope, we pre-programmed set points for picture, which removes bias, and used the Keyence analysis software to directly measure micrometer size of the spheres. In this second method, the diameter measurement was more straightforward, and unbiased. Further, we only calculated spheres with greater than 75 �m to avoid including aggregates. Results from both methods showed the same result. In terms of new and better images, we will need to perform the experiment again. Under normal circumstances, we would be more than happy to do it. But, unfortunately, due to COVID-19 associated lab and institution closure, we cannot perform new experiments. For the representative images in Figure 3, we have enlarged our existing pictures (as much as possible while maintaining good image quality) for better visualization of the spheres.

Then, to show an increase in stemness features only spheres formation it's not enough, the Author should at least show an increase of stem-associated-genes such as Nanog, OCT3/4, and Sox-2 or perform side population assay, or ALDH or any other assay appropriated for MB. This is valid as well for the CD133 knock down.

Response: We appreciate the reviewer suggestion, and did perform Sox2 western blot (Fig. 3F), which is also a stem marker \[2\] and found no difference between ACM-conditioned and DMEM-conditioned MB cells. Due to current COVID-19 situation, we are unable to perform other stem marker genes as requested. We have therefore made revisions in the text to de-emphasize the stemness point.

Discussion should be more focused and less speculative.

Response: We have made extensive changes to the discussion to make the points that are directly relevant to the data in the manuscript, and those that support or oppose existing literature on this subject.

We thank the reviewers for spending their valuable time providing us feedback on our manuscript.
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Dear Dr. Ramchandran,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

The Authors only partly positively responded to the comments previously raised by the two referees. In their answer the Authors wrote that they were unable to perform extra experiments due to the SARS-COV-2 pandemia. This Editor understand that the problem is real but asks the Authors to obtain much more time for research completion. Therefore The Authors are allowed to ask for more time to send their revised manuscript.

==============================

We would appreciate receiving your revised manuscript by Jun 19 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Gianpaolo Papaccio, M.D., Ph.D.

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The Authors do not fully address my previous concerns. They state that, due to current COVID-19 situation, they are unable to perform experiments requested by this reviewer. I recommend asking to editor more time to carry out the experiments in order to improve the manuscript.

Reviewer \#2: the author have addressed part of the comments raised by this reviewer, accoridng to author\'s responce they cannot perform required experiment because of the covid-19 spread and lab closure. Due to this situation I believ it will be more approriate a time extention so the revisin can be perform at the best.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 1

10 Jun 2020

REVIEWER RESPONSE LETTER

Re: PONE-D-20-06629: Astrocytes influence medulloblastoma phenotypes and CD133 surface expression

Editor Comments: The Authors only partly positively responded to the comments previously raised by the two referees. In their answer the Authors wrote that they were unable to perform extra experiments due to the SARS-COV-2 pandemia. This Editor understand that the problem is real but asks the Authors to obtain much more time for research completion. Therefore, the authors are allowed to ask for more time to send their revised manuscript.

Reviewer \#1: The Authors do not fully address my previous concerns. They state that, due to current COVID-19 situation, they are unable to perform experiments requested by this reviewer. I recommend asking to editor more time to carry out the experiments in order to improve the manuscript.

Reviewer \#2: the author have addressed part of the comments raised by this reviewer, according to author\'s responce they cannot perform required experiment because of the covid-19 spread and lab closure. Due to this situation I believe it will be more appropriate a time extension so the revising can be performed at the best.

Response: Thank you for the additional time that the editor provided to perform additional experiments and make more revisions to the manuscript. As per the reviewer and editor requests, we have now performed additional experiments and included new data in the following panels Figs. 3C, 3D, and 3F.

New images for neurospheres were requested. We performed a new experiment to generate newer images under higher power to honor this request. All of our previous images were low power. This new higher magnified image data is now included in figure 3C with scale bars. The neurosphere sizes are clearly larger in the astrocyte-conditioned media (ACM) compared to DMEM conditions. Further, the ACM-induced neurospheres are similar in size to DMEM:F12 positive control conditions. The new images were quantified, and the quantification is also provided in the figure 3D.

Western blots for additional stem cell proteins (Nanog & Oct4) were requested in addition to previously provided Nestin (Fig. 3E) and Sox2 (Fig. 3G) data. We performed westerns for Oct-4 and Nanog, and have provided new data for Oct4 (Fig. 3F) along with quantification. The Oct-4A blot shows that under both ACM and DMEM:F12 positive control conditions, Oct-4A protein (\*\*\*p\<0.001) expression was higher compared to DMEM conditions. We checked Nanog protein as well, but the antibody did not work well, and thus no conclusion can be further derived from this blot. Collectively, of the three stemness proteins that were detected in MB cells, we noticed 2 (Nestin and Oct-4A) out of 3 expression to be higher in ACM conditions compared to DMEM conditions.

Stemness write-up de-emphasis. We carefully searched for the entire manuscript for the stemness or stem cell word, and only found that we utilized these words in reference to describing CD133 as a stem cell marker or describing Nestin, Sox2 or Oct-4A proteins in the results section. The Discussion section was extensively revised in the previous submission, and all references to stemness was removed then.
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PONE-D-20-06629R2

Dear Dr. Ramchandran,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Gianpaolo Papaccio, M.D., Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

Reviewer \#2: The Authors have adressed al the concerns raised by this reviewer. Now the manuscript is greatly improved.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No
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PONE-D-20-06629R2

Astrocytes influence medulloblastoma phenotypes and CD133 surface expression

Dear Dr. Ramchandran:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Gianpaolo Papaccio

Academic Editor

PLOS ONE
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